Hepatocellular carcinoma (HCC), the most frequent subtype of liver cancer, is the third leading cause of cancer death in the world. About 50 to 80% of HCC cases are caused by Hepatitis B virus (HBV) infection, a major health problem that afflicts 270 million people worldwide.
Our lead product, LioCyx-M, an autologous T-cell product transfected with mRNA encoding HBV antigen-specific TCR, has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post liver transplant.
Lion TCR is committed to providing safe and effective investigational therapies to patients in need through clinical studies.
Contact us at firstname.lastname@example.org for more information.
There may, however, be circumstances when patients who are seriously ill have exhausted all available treatment and are not be eligible for our clinical trials.
In those cases, patients may be eligible for treatment with an investigational therapy through programs referred to as ‘Expanded Access Programs’ (EAPs) or ‘compassionate use’.
For our EAP, please click here for more information.
Study Type: Single center, single arm, open-labelPhase 1 study
Objective: To assess the safety and efficacy of LioCyx-M for patients with recurrent HBV-related HCC post liver transplantation
Study Type: Single center, single arm, open-label Phase 1 study
Objective: To assess the safety and efficacy of LioCyx-M for patients with advanced primary HBV-HCC